Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access the Media Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
Related stories
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its New Drug
Application (NDA) for DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial.
This NDA provides for the use of DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial for locally
advanced or metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and hormone
refractory metastatic prostate cancer
Latest stories
Related stories
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Media Packs
Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!
– Access theMedia Pack Now
– Book a Conference Call
– Leave Message for Us to Get Back
World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives.
Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.
